[Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity]

B Perrouin-Verbe; A Ruffion; X Gamé; P Denys; J Kerdraon; G Karsenty; M de Sèze; F Haab; C Saussine; J-M Soler; G Amarenco; E Chartier-Kastler

doi:10.1016/j.purol.2009.02.006

[Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity]

Prog Urol. 2009 Jun;19(6):372-82. doi: 10.1016/j.purol.2009.02.006. Epub 2009 Apr 3.

[Article in French]

Authors

B Perrouin-Verbe¹, A Ruffion, X Gamé, P Denys, J Kerdraon, G Karsenty, M de Sèze, F Haab, C Saussine, J-M Soler, G Amarenco, E Chartier-Kastler

Affiliation

¹ Service de médecine physique et de réadaptation neurologique, hôpital Saint-Jacques, CHU de Nantes, 85, rue Saint-Jacques, 44093 Nantes cedex, France. brigitte.perrouinverbe@chu-nantes.fr

PMID: 19467455
DOI: 10.1016/j.purol.2009.02.006

Abstract

Botulinum toxin A intradetrusor injections have revolutionised the treatment of neurogenic detrusor overactivity. Based on a systematic literature review, the french speaking group of neuro-urology (Genulf) propose clinical guidelines concerning the indications of the first injection.

Publication types

English Abstract

MeSH terms

Botulinum Toxins, Type A / therapeutic use*
Humans
Injections
Neuromuscular Agents / therapeutic use*
Urinary Bladder, Neurogenic / drug therapy*

Substances

Neuromuscular Agents
Botulinum Toxins, Type A